US EditionSudden Sight Loss Warning for Anyone Using Wegovy
A study of 31,774 FDA reports found Wegovy's risk of ischemic optic neuropathy is nearly five times higher than Ozempic's, with men at triple the risk versus women.
- In an analysis of 31,774 semaglutide reports, researchers found Wegovy was associated with a nearly fivefold higher risk of ischemic optic neuropathy versus Ozempic, based on FAERS data.
- Dose-Focused analysis found Wegovy uses a higher maximum dose than Ozempic , with researchers urging prospective evaluation of this dose-dependent ION risk.
- Analysis of case counts found 28 ION reports with Wegovy, 40 with Ozempic, and reporting odds ratios of 74.9 for Wegovy versus 18.8 for Ozempic.
- Regulators noted that Novo Nordisk said it updates EU leaflets but found data did not suggest causality; ophthalmologists report rising patient questions, as 'I actually have patients ask me about this', Banik said.
- With use set to grow, researchers note media attention and FAERS limitations may have influenced reporting, precluding true incidence determination amid the UK’s 29% obesity and growing prescriptions.
19 Articles
19 Articles
Experts Warn: 1 in 10,000 Wegovy Users Face 5X Higher Risk Leading to Serious Eye Complications
A new study has warned that one in every 10,000 people taking Wegovy could suffer a sudden, permanent loss of sight, with the risk five times higher than those on Ozempic. While these eye strokes are rare, they are serious, and the findings raise questions about the safety of users of weight-loss drugs. Wegovy, Ozempic, and Rybelsus contain the active ingredient semaglutide. They're prescribed to help manage blood sugar levels and curb appetite.…
Wegovy jab users face risk of 'eye stroke' five times greater than patients on Ozempic
Patients using Wegovy face a risk of sudden vision loss nearly five times greater than those prescribed Ozempic, new research published in the British Journal of Ophthalmology has revealed.The large-scale investigation, conducted by Canadian researchers, examined adverse event reports submitted to the US Food and Drug Administration between December 2017 and December 2024.Both medications contain the active ingredient semaglutide, manufactured b…
New research suggests that certain popular weight loss and diabetes medications may be linked to a rare but serious eye problem.
Coverage Details
Bias Distribution
- 46% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
